Reconstitute in water to a concentration of 0.1 to 1.0 mg/ml. Note: Due to solubility reasons the protein should be kept at low pH. This solution can then be diluted into other aqueous buffers. Store at -20ºC.
Purity was assessed by SDS-PAGE (≥95%) and by HPLC (≥95%).
For laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
Noggin belongs to a group of diffusible proteins which bind to ligands of the TGF-beta family and regulate their activity by inhibiting their access to signaling receptors. Noggin was originally identified as a BMP-4 antagonist whose action is critical for proper formation of the head and other dorsal structures. Consequently, Noggin has been shown to modulate the activities of other BMPs including BMP-2,-7,-13, and -14. Targeted deletion of Noggin in mice results in prenatal death and recessive phenotype displaying a severely malformed skeletal system. Conversely, transgenic mice over-expressing Noggin in mature osteoblasts display impaired osteoblastic differentiation, reduced bone formation, and severe osteoporosis. Recombinant human Noggin is a 23.1 kDa non-disulfide-linked homodimer consisting of a total of 206 amino acid residues.